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ABSTRACT
Objective: To assess the prevalence of sexual dysfunction in women followed up at the Rheumatology Outpatient 
Clinic of the Hospital Universitário de Brasília and of the Hospital das Clínicas da Universidade de São Paulo with the 
following rheumatic diseases: systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis; antiphospholipid 
antibody syndrome; and ¿ bromyalgia. Methods: The Female Sexual Function Index (FSFI), obtained by applying a 
19-item questionnaire that assesses six domains (sexual desire, arousal, vaginal lubrication, orgasm, sexual satisfac-
tion and pain), was used. Results: This study assessed 163 patients. The mean age was 40.4 years. The prevalence of 
sexual dysfunction was 18.4%, but 24.2% of the patients reported no sexual activity over the past 4 weeks. Patients 
with ¿ bromyalgia and systemic sclerosis had the highest sexual dysfunction index (33%). Excluding patients with no 
sexual activity, the sexual dysfunction rate reaches 24.2%. Conclusion: The prevalence of sexual dysfunction found in 
this study was lower than that reported in the literature. However, 24.2% of the patients interviewed reported no sexual 
activity over the past 4 weeks, which might have contributed to the low sexual dysfunction index found. 
Keywords: sexuality, sexual dysfunction, rheumatic diseases, quality of life, sexual behavior.
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INTRODUCTION
Sexuality is part of human life and of quality of life, accoun-
ting for individual well-being. It relates not only to sexual 
intercourse itself, but also to a whole spectrum that ranges 
from self-image and self-valuing to relationship with the 
‘Other’. Appropriate sexual activity comprises phases from 
sexual arousal to relaxation, with pleasure and satisfaction.1
Sexual dysfunction is a change in a phase of the sexual 
activity that can culminate in frustration, pain, and a reduction 
in the number of sexual intercourses.2 Some studies have sho-
wn a prevalence of sexual dysfunction in the general female 
population of as much as 40%.3 Chronic diseases are known 
to inÀ uence the quality of sexual life, but their effect is little 
studied, and sexual dysfunction, little diagnosed.2 This is due 
to two reasons: patients do not report their sexual dysfunctions 
because of shame or frustration, and physicians rarely ask their 
patients about those dysfunctions.3,4 
When asked, health professionals allege to have little time 
for consultation, lack of privacy in their medical of¿ ces, and 
lack of ability to discuss the issue. In addition, patients tend 
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to avoid speaking about that subject. Recently, the Association 
Nationale de Défense Contre l’Arthrite Rhumatoïde (French 
Association for Rheumatoid Arthritis) has sent, via e-mail, a 
questionnaire about sexuality to their members. Only 38% 
responded, and 70% reported a negative impact of the disease 
on their sexual life. Seventy-two per cent reported never having 
spoken with their physicians about sexuality.4
Studies on the Brazilian population that could help to 
delineate the real impact of rheumatic diseases on sexual 
functioning still lack. Knowing the extension of the problem 
is necessary, so that therapeutic possibilities can be provided, 
because sexual dysfunction is one of the major determinants 
of reduced quality of life. 
This study aimed at assessing the prevalence of sexual 
dysfunction in women followed up in the Rheumatology 
Outpatient Clinic of the Hospital Universitário de Brasília 
(HUB) and the Hospital das Clínicas of the Universidade de 
São Paulo (HC-FMUSP), who have the following rheumatic 
diseases: systemic lupus erythematosus (SLE); rheumatoid 
arthritis (RA); systemic sclerosis (SSc); antiphospholipid 
antibody syndrome (APLS); and ¿ bromyalgia (FM). 
PATIENTS AND METHODS
This study assessed 163 women followed up at the 
Rheumatology Outpatient Clinic of the HUB and HC-FMUSP 
(patients with APLS). Those women had been diagnosed with 
RA, SLE, SSc, FM, and APLS.
The presence of sexual dysfunction was identi¿ ed by use of 
the Female Sexual Function Index (FSFI), obtained by applying 
the questionnaire proposed by Rosen et al.,5,6 which is widely 
used in several countries and whose Portuguese version has been 
validated7 (Table 1). That questionnaire contains 19 items that 
assess the following six domains: sexual desire; arousal; vaginal 
Table 1
Female sexual function index (FSFI)
Instructions
This questionnaire asks about your sexual life over the past 4 weeks. Please answer the questions as honestly and clearly as possible.
Your answers will be kept secret. To answer the questions, use the following deﬁ nitions:
Sexual activity: comprises caressing, foreplay, masturbation (“jerking off”/female masturbation) and sexual act.
Sexual act: penetration (insertion) of the penis into the vagina.
Sexual stimulus: includes situations such as fondling the partner, sexual auto-stimulation (masturbation) or sexual fantasy (thoughts).
Sexual desire or drive: includes the disposition to engage in sexual activity, to feel receptive to 
the sexual initiative of a partner, and to think about or fantasize with sex.
Sexual excitement or arousal: sensation that includes physical and mental aspects. It might include sensations 
such as genital heat or swelling, lubrication (feeling wet/“wet vagina”) or muscle contractions.




1) Over the past 4 weeks, how often did you feel sexually aroused 
(“turned on”) during sexual activity or intercourse?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
2) Over the past 4 weeks, how would you rate your level of sexual 
arousal (“turn on”) during sexual activity or intercourse?





6. Very low or none at all.
3) Over the past 4 weeks, how often did you feel sexual desire or interest?
1. Almost always or always.
2. Most times (more than half the time).
3. Sometimes (about half the time).
4. A few times (less than half the time).
5. Almost never or never.
4) Over the past 4 weeks, how would you rate your level (degree) of 





5. Very low or none at all.
5) Over the past 4 weeks, how conﬁ dent were you about becoming 
sexually aroused during sexual activity or intercourse?
1. No sexual activity.
2. Very high conﬁ dence.
3. High conﬁ dence.
4. Moderate conﬁ dence.
5. Low conﬁ dence.
6. Very low or no conﬁ dence.
6) Over the past 4 weeks, how often have you been satisﬁ ed with your 
arousal (excitement) during sexual activity or intercourse?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
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Table 1 (continued)
Female sexual function index (FSFI)
7) Over the past 4 weeks, how often did you become lubricated 
(“wet”) during sexual activity or intercourse?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
8) Over the past 4 weeks, how difﬁ cult was it to become lubricated 
(“wet”) during sexual activity or intercourse?
1. No sexual activity.
2. Extremely difﬁ cult or impossible.
3. Very difﬁ cult.
4. Difﬁ cult.
5. Slightly difﬁ cult.
6. Not difﬁ cult.
9) Over the past 4 weeks, how often did you maintain your lubrication 
(“wetness”) until completion of sexual activity or intercourse?
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
10) Over the past 4 weeks, how difﬁ cult was it to maintain your 
lubrication (“wetness”) until completion of sexual activity or 
intercourse?
1. No sexual activity.
2. Extremely difﬁ cult or impossible.
3. Very difﬁ cult.
4. Difﬁ cult.
5. Slightly difﬁ cult.
6. Not difﬁ cult.
11) Over the past 4 weeks, when you had sexual stimulation or 
intercourse, how often did you reach orgasm (climax)?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
12) Over the past 4 weeks, when you had sexual stimulation or 
intercourse, how difﬁ cult was it for you to reach orgasm (climax)?
1. No sexual activity.
2. Extremely difﬁ cult or impossible.
3. Very difﬁ cult.
4. Difﬁ cult.
5. Slightly difﬁ cult.
6. Not difﬁ cult.
13) Over the past 4 weeks, how satisﬁ ed were you with your ability to 
reach orgasm (climax) during sexual activity or intercourse?
1. No sexual activity.
2. Very satisﬁ ed.
3. Moderately satisﬁ ed.
4. About equally satisﬁ ed and dissatisﬁ ed.
5. Moderately dissatisﬁ ed.
6. Very dissatisﬁ ed.
14) Over the past 4 weeks, how satisﬁ ed have you been with the 
amount of emotional closeness during sexual activity between you and 
your partner?
1. No sexual activity.
2. Very satisﬁ ed.
3. Moderately satisﬁ ed.
4. About equally satisﬁ ed and dissatisﬁ ed.
5. Moderately dissatisﬁ ed.
6. Very dissatisﬁ ed.
15) Over the past 4 weeks, how satisﬁ ed have you been with your 
sexual relationship with your partner?
1. No sexual activity.
2. Very satisﬁ ed.
3. Moderately satisﬁ ed.
4. About equally satisﬁ ed and dissatisﬁ ed.
5. Moderately dissatisﬁ ed.
6. Very dissatisﬁ ed.
16) Over the past 4 weeks, how satisﬁ ed have you been with your 
overall sexual life?
1. No sexual activity.
2. Very satisﬁ ed.
3. Moderately satisﬁ ed.
4. About equally satisﬁ ed and dissatisﬁ ed.
5. Moderately dissatisﬁ ed.
6. Very dissatisﬁ ed.
17) Over the past 4 weeks, how often did you experience discomfort 
or pain during vaginal penetration?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
18) Over the past 4 weeks, how often did you experience discomfort 
or pain following vaginal penetration?
1. No sexual activity.
2. Almost always or always.
3. Most times (more than half the time).
4. Sometimes (about half the time).
5. A few times (less than half the time).
6. Almost never or never.
19) Over the past 4 weeks, how would you rate your level (degree) of 
discomfort or pain during or following vaginal penetration?





6. Very low or none at all.
SCORING SYSTEM







Desire 1, 2 1–5 0.6 1.2 6.0
Arousal 3, 4, 5, 6 0–5 0.3 0.0 6.0
Lubrication 7, 8, 9, 10 0–5 0.3 0.0 6.0
Orgasm 11, 12, 13 0–5 0.4 0.0 6.0
Satisfaction 14, 15, 16 0 (ou 1) –5 0.4 0.8 6.0
Pain 17, 18, 19 0–5 0.4 0.0 6.0
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lubrication; orgasm; sexual satisfaction; and pain. Individual 
domain scores are obtained by adding the scores of the indivi-
dual items that comprise the domain and multiplying the sum 
by the domain factor. The full scale score is obtained by adding 
the six domain scores. Values  26 indicate sexual dysfunction.
The study’s inclusion criteria were as follows: 18–69-year-
-old women diagnosed with speci¿ c diseases (RA, SLE, SSc, 
FM, APLS) by a rheumatologist according to the American 
College of Rheumatology criteria and Sidney criteria for 
APLS,8–13 and who had had at least one sexual intercourse in 
life. Those who refused to participate in the study and those 
whose questionnaires were not fully completed were excluded.
The following demographic and clinical data of the partici-
pants were collected: diagnosis; disease duration; age; religion; 
educational level; marital status; medications used; date of 
the last period; and use of hormone replacement therapy. This 
study was approved by the Committee on Ethics and Research 
of the Universidade de Brasília.
Statistical analysis
Categorical variables were described as absolute frequency 
and percent relative frequency. Quantitative variables were 
described as mean ± standard deviation, when their distribu-
tion was symmetrical, or as median and interquartile interval, 
when asymmetrical. 
RESULTS
This study selected 181 patients, 18 of whom were ex-
cluded due to the following reasons: misunderstanding in 
questionnaire completion (5); virginity (1); and incomplete 
questionnaire (items left unanswered) (12). The disease dis-
tribution of the 163 patients remaining in the study was as 
follows: SLE, 82 patients; RA, 24; FM, 15; SSc, 3; and APLS, 
39 (all patients with primary APLS) (Table 2).
The mean age of the patients was 40.4 years. The cha-
racteristics of the participants according to their diseases are 
shown in Table 3. Regarding menstruation, 46% had regular 
cycles and 28.7% were in menopause. Only one patient was 
on hormone replacement therapy. Most patients (76%) had 
more than 7 years of schooling and only 1.2% were illiterate. 
Table 2
Demographic data and menstrual cycle of all patients studied 
and drugs used
























HRT = Hormone replacement therapy.
Table 3
Demographic data, disease duration, educational level (years of schooling) and frequency of sexual dysfunction in several 
rheumatic diseases studied 
General SLE RA FM SSc APLS
Number of patients 163 (100%) 82 (50%) 24 (14.7%) 15 (9.2%) 3 (1.8%) 39 (24%)
Mean 40.4 36.1 41.2 50.4 45 40.1
Age (SD) 10.9 10.1 8.5 7.5 — 11.4
Median 40 34 40 51 45 40
Disease duration (years) — 7.6 8.3 6.2 2.5 9.4
Schooling 
Illiterate




















Sexual dysfunction 18.4% 22% 8.3% 33.3% 33.3% 10.2%
No sexual activity 24.2% 17% 17% 47% 0 36%
SD: standard deviation; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; FM: ﬁ bromyalgia; SSc: systemic sclerosis; APLS: antiphospholipid syndrome.
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The patients reported the following marital status: 
married, 51.5%; single, 21.7%; living with partner, 13.6%; 
separated, 7.4%; and widow, 5.6%. For the purpose of this 
study, those married and those living with their partners were 
gathered in one group, called the long-time companionship 
group, corresponding to 65.1% of the interviewees. Most 
participants reported being Catholic (41.2%). 
The prevalence of sexual dysfunction was 18.4%, but 
24.2% of the patients reported no sexual activity over the 
previous 4 weeks. The prevalence of sexual dysfunction 
according to the subgroups of disease was as follows: FM 
and SSc, 33.3% of the patients (the highest rate); SLE, 22% 
of the patients; RA, 8.3% of the patients; and APLS, 10.2% 
of the patients. Excluding the patients with no recent sexual 
activity, the prevalence of sexual dysfunction reaches 24.2%.
The mean number of medications per patient was 3.4. The 
most used drugs were À uoxetine and tricyclic antidepressants 
(18.7%). Both drugs were more often used by patients with 
FM (12 patients), followed by those with SLE (7), RA (3) 
and SSc (2). The mean FSFI score of patients on À uoxetine 
or tricyclic antidepressants was 30.4. Patients not on those 
drugs had a mean score of 19.51.
DISCUSSION
Rheumatic diseases can interfere with sexual function due to 
factors related to both the disease itself and its treatment.1,14 
Pain, morning stiffness, joint edema and fatigue might both 
lead to a decrease in sexual drive and impair sexual inter-
course. In addition, low self-esteem and negative body image, 
which usually affect individuals with rheumatic diseases, are 
relevant psychological factors. The drugs used to treat those 
diseases can also reduce libido.2,15,16 
A few studies have assessed the impact of rheumatic disea-
ses on sexual function. A study conducted in Cleveland, USA, 
has shown a lower frequency of sexual activity and reduced 
vaginal lubrication in patients with SLE as compared with 
controls.14 Patients with SLE have also reported an increase 
in vaginal discomfort or pain during intercourse; however, 
sexual drive, motivation, arousal and climaxing were similar 
to those in controls.14,17
The prevalence of sexual dysfunction found in this study 
was lower than that reported in the literature. Research with 
individuals with RA has shown a 50%–60% impact on their 
quality of sexual life.1 Abdel-Nasser et al.18 have studied 52 
women with RA, 60% of whom had reported a decrease in their 
sexual drive and satisfaction, as well as in sexual performance. 
Ayden et al.1, using the FSFI questionnaire in patients with 
FM, have reported 54.2% of sexual dysfunction versus 15.8% 
in controls. However, Impens et al.19 have applied that same 
questionnaire to patients with SSc and have found a mean score 
of 24, but with a high sexual abstinence rate (40%). 
An Egyptian study14 on RA has reported sexual dysfunc-
tion in 60% of the patients studied, with libido loss or decrease 
in 46% of them, and that correlated with disease activity 
parameters. Joint pain can restrict certain sexual positions, 
mainly in the presence of knee or hip joint impairment.18 
Other studies have also shown a trend towards more sexual 
dysfunction in patients with RA.1,4,14 In this study, sexual 
dysfunction was found in 8.3% of the patients with RA, whi-
ch is lower than that reported in other studies on the theme.
The few studies on SSc have shown a reduction in sexual 
activity due to psychological and physical factors, such as 
vaginal dryness and ulcerations.19,20 In addition, skin thick-
ness might lead to joint contractures, resulting in dif¿ culties 
to sexual relationship.20 Our study assessed only 3 patients 
with SSc, which hinders other conclusions about the theme.
Regarding FM, depression seems to be the determinant 
factor for sexual dysfunction,21 which, in those patients, ma-
nifests mainly as a reduction in sexual drive21,1 and in orgasm 
rate, in addition to pain during sexual intercourse.22 In our 
study, the patients with FM had the highest sexual dysfunction 
rate (33%) and the highest percentage of sexual abstinence 
(47%), in accordance with reports in the literature. Depression 
is extremely common in FM, being associated with reduced 
libido and self-esteem, being, thus, an important factor in 
sexual dysfunction.1
In addition, the use of antidepressants worsens or contri-
butes to worsen the quality of sexual life. As much as 60% of 
patients on serotonin uptake inhibitors have sexual dysfunc-
tion.16 Tricyclic antidepressants, serotonin uptake inhibitors 
and monoamine oxidase inhibitors are the antidepressants that 
most reduce libido.15 In this study, a considerable increase 
in the FSFI score of the patients on À uoxetine and tricyclic 
antidepressants was observed, as compared to those not using 
those drugs (30.4 versus 19.51). 
Of the patients interviewed, 24.2% reported no sexual 
activity over the previous 4 weeks, which might have contri-
buted to the low sexual dysfunction rate found in our study. 
Some of those patients might have some degree of sexual 
dissatisfaction or dif¿ culty, which might lead to abstinence 
or a reduction in the frequency of sexual intercourses. 
The educational level was high, with 76% of the partici-
pants having more than 7 years of schooling. Nevertheless, 
dif¿ culty in understanding the questions might have occurred. 
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The questionnaire is a self-report tool (except in cases of 
illiteracy, when the doctor met the answers),  but many pa-
tients asked about the meaning of certain items. In addition, 
17 patients were excluded because of a misunderstanding 
in questionnaire completion or lack of answer to any item. 
The quality of sexual life is still rarely assessed during me-
dical consultations. Further studies are required to delineate 
the impact of disease on sexuality and to make rheumatolo-
gists aware of the importance of discussing those questions 
with their patients. 
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